logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma set to expand Clevegen cancer trial as data continues to impress

Faron Pharmacuetical Oy’s (LON:FARN) clinical trial of anti-cancer drug Clevegen continues to deliver encouraging results chief executive Markku Jalkanen told Proactive’s Andrew Scott.

Dosing has now reached the maximum levels with no adverse effects on patients in the study, while significant signs of increased immune activity were noted.

Nine people have now been treated and once the drug’s safety has been established, Faron will increase the number and type of patients.

Colorectal cancer will be the initial focus, but Jalkanen wants to expand into other forms of difficult to treat cancers such as liver, melanoma and pancreatic.

“Once we’ve optimised the dosing we can move into cohort escalation. The first target will be CRC but if there are strong clinical efficacy signs we can expand even further.”

Quick facts: Faron Pharmaceuticals Ltd

Price: 147.5 GBX

AIM:FARN
Market: AIM
Market Cap: £63.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read